In their study, the researchers discovered that there is a correlation between the rise in p16 during cellular aging and the increase in PD-L1 levels. They also worked out the molecular mechanism ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Once it attaches, it blocks the action this protein has with another protein called programmed death ligand-1 (PD-L1). PD1 and PD-L1 work together to stop your immune system from performing some ...

Click here to read the article now. PD-L1 biomarker testing guides cancer treatment decisions. These results are difficult to access because laboratory reports are unstructured and require ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma. Sun Pharma announced ...